The aims of this study were * to analyze CD160 expression in both normal and pathological eyes from human adults * to evaluate association between CD160 presence on endothelial cells from blood vessels and retinal vascular disease
Anti-angiogenic agents stand first in the treatment of neovascular diseases of the retina. Intravitreal injections of anti-Vascular Endothelial Growth Factor (VEGF) agents have emerged over the past decade as the first line of treatment in some neovascular diseases of the retina. Nevertheless, anti-VEGF therapies suffer some limitations, among which a short time to recurrence (1 week to 3 months) of retinal neovascularization and an eroding biological effect after prolonged use and. CD160 appeared in several experimental studies as a marker of activated endothelial cells, suggesting it could represent a promising target for novel anti-angiogenic.
Study Type
OBSERVATIONAL
Enrollment
75
Chu Reims
France, Reims, France
CD160 staining intensity score
Formalin fixed and paraffin embedded blocks were used for immunohistochemistry using CD160. The immunolabelling was evaluated independently by 2 observers (CBR, AH) blinded to clinical data. The staining intensity (0: absent, 1: faint, 2: moderate, 3: strong) was assessed for CD160 immunolabelling.
Time frame: Day0
CD105 staining intensity score
Formalin fixed and paraffin embedded blocks were used for immunohistochemistry using CD105. The immunolabelling was evaluated independently by 2 observers (CBR, AH) blinded to clinical data. The staining intensity (0: absent, 1: faint, 2: moderate, 3: strong) was assessed for CD105 immunolabelling.
Time frame: Day0
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.